Egetis Therapeutics AB (publ)
SSE:EGTX.ST
6.07 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 46.1 | 57.6 | 22.5 | 38.243 | 40.662 | 82.562 | 28.211 | 13.585 | 0 | 0 | 0 | 0 | 0 | 0 | 0.003 | 0 | 0 |
| Cost of Revenue
| 11.6 | 204.5 | 142.6 | 96.527 | 185.171 | 112.24 | 83.855 | 74.197 | 19.513 | 26.093 | 29.459 | 10.558 | 18.601 | 0 | 0 | -0.733 | -0.509 |
| Gross Profit
| 34.5 | -146.9 | -120.1 | -58.284 | -144.509 | -29.678 | -55.644 | -60.612 | -19.513 | -26.093 | -29.459 | -10.558 | -18.601 | 0 | 0.003 | 0.733 | 0.509 |
| Gross Profit Ratio
| 0.748 | -2.55 | -5.338 | -1.524 | -3.554 | -0.359 | -1.972 | -4.462 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 146.2 | 0 | 136.3 | 88.671 | 183.276 | 112.239 | 83.855 | 74.197 | 19.513 | 26.093 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 105.6 | 86.2 | 0 | 14.513 | 11.097 | 13.334 | 11.325 | 15.626 | 13.162 | 11.274 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 109.7 | 86.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.074 | 2.957 | 0 | 0 |
| SG&A
| 215.3 | 172.8 | 74.3 | 14.513 | 11.097 | 13.334 | 11.325 | 15.626 | 13.162 | 11.274 | 19.357 | 6.025 | 17.376 | 8.074 | 2.957 | 0 | 0 |
| Other Expenses
| 2.4 | 0 | 54.7 | 32.286 | 22.546 | 23.596 | 20.032 | 10.895 | 0.132 | 0.145 | -12.712 | -9.603 | -9.214 | 26.151 | 0.846 | 2.078 | 1.07 |
| Operating Expenses
| 363.9 | 177.9 | 54.7 | 46.799 | 33.643 | 36.93 | 31.357 | 26.521 | 18.68 | 18.183 | 6.273 | 6.027 | 7.61 | 34.225 | 3.803 | 2.078 | 1.07 |
| Operating Income
| -329.4 | -324.8 | -198.1 | -105.681 | -178.395 | -66.681 | -92.514 | -88.097 | -38.363 | -44.028 | -48.566 | -26.084 | -35.31 | -34.225 | -3.801 | -1.346 | -0.561 |
| Operating Income Ratio
| -7.145 | -5.639 | -8.804 | -2.763 | -4.387 | -0.808 | -3.279 | -6.485 | 0 | 0 | 0 | 0 | 0 | 0 | -1,425.574 | 0 | 0 |
| Total Other Income Expenses Net
| -13.8 | -2 | 4.3 | 1.181 | -0.725 | 5.259 | 1.891 | 0.162 | 0.14 | 0.192 | 0.146 | 0.535 | 1.453 | 0.979 | -0 | -0 | 0.002 |
| Income Before Tax
| -343.2 | -326.8 | -193.8 | -104.542 | -179.12 | -61.422 | -85.003 | -87.935 | -38.223 | -43.836 | -48.42 | -25.549 | -33.857 | -33.246 | -3.801 | -1.346 | -0.559 |
| Income Before Tax Ratio
| -7.445 | -5.674 | -8.613 | -2.734 | -4.405 | -0.744 | -3.013 | -6.473 | 0 | 0 | 0 | 0 | 0 | 0 | -1,425.59 | 0 | 0 |
| Income Tax Expense
| 0.3 | 0.1 | -4.3 | 0.188 | 0.001 | 0.007 | 1.838 | -0.964 | -0.17 | 0.45 | 0.399 | 0.829 | 1.569 | 1.017 | 0 | 0 | 0 |
| Net Income
| -343.6 | -326.9 | -189.5 | -104.73 | -179.121 | -61.429 | -85.003 | -87.935 | -38.223 | -43.836 | -48.42 | -25.549 | -33.857 | -33.246 | -3.801 | -1.346 | -0.559 |
| Net Income Ratio
| -7.453 | -5.675 | -8.422 | -2.739 | -4.405 | -0.744 | -3.013 | -6.473 | 0 | 0 | 0 | 0 | 0 | 0 | -1,425.59 | 0 | 0 |
| EPS
| -0.99 | -1.27 | -0.98 | -0.58 | -2.44 | -1.08 | -1.58 | -1.63 | -1.16 | -1.4 | -1.61 | -0.92 | -1.24 | -1.5 | -10.33 | -4.19 | -0.028 |
| EPS Diluted
| -0.98 | -1.26 | -0.98 | -0.58 | -2.44 | -1.08 | -1.58 | -1.63 | -1.16 | -1.4 | -1.61 | -0.92 | -1.24 | -1.5 | -10.33 | -4.19 | -0.028 |
| EBITDA
| -317.4 | -319.1 | -191 | -101.899 | -177.628 | -61.205 | 0 | -87.935 | -38.223 | -44.129 | -48.607 | -26.186 | -33.853 | -16.111 | -3.798 | -1.343 | -0.557 |
| EBITDA Ratio
| -6.885 | -5.54 | -8.489 | -2.665 | -4.368 | -0.741 | 0 | -6.473 | 0 | 0 | 0 | 0 | 0 | 0 | -1,424.784 | 0 | 0 |